1. Home
  2. BCAB vs GNSS Comparison

BCAB vs GNSS Comparison

Compare BCAB & GNSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • GNSS
  • Stock Information
  • Founded
  • BCAB 2007
  • GNSS 1992
  • Country
  • BCAB United States
  • GNSS United States
  • Employees
  • BCAB N/A
  • GNSS N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • GNSS Consumer Electronics/Appliances
  • Sector
  • BCAB Health Care
  • GNSS Consumer Staples
  • Exchange
  • BCAB Nasdaq
  • GNSS Nasdaq
  • Market Cap
  • BCAB 40.5M
  • GNSS 112.9M
  • IPO Year
  • BCAB 2020
  • GNSS N/A
  • Fundamental
  • Price
  • BCAB $0.71
  • GNSS $2.17
  • Analyst Decision
  • BCAB Hold
  • GNSS Strong Buy
  • Analyst Count
  • BCAB 3
  • GNSS 1
  • Target Price
  • BCAB $1.00
  • GNSS $5.75
  • AVG Volume (30 Days)
  • BCAB 1.4M
  • GNSS 275.7K
  • Earning Date
  • BCAB 11-05-2025
  • GNSS 12-08-2025
  • Dividend Yield
  • BCAB N/A
  • GNSS N/A
  • EPS Growth
  • BCAB N/A
  • GNSS N/A
  • EPS
  • BCAB N/A
  • GNSS N/A
  • Revenue
  • BCAB $11,000,000.00
  • GNSS $30,470,000.00
  • Revenue This Year
  • BCAB N/A
  • GNSS $90.97
  • Revenue Next Year
  • BCAB N/A
  • GNSS $75.75
  • P/E Ratio
  • BCAB N/A
  • GNSS N/A
  • Revenue Growth
  • BCAB N/A
  • GNSS 8.95
  • 52 Week Low
  • BCAB $0.24
  • GNSS $1.46
  • 52 Week High
  • BCAB $2.53
  • GNSS $4.04
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 49.79
  • GNSS 46.69
  • Support Level
  • BCAB $0.61
  • GNSS $2.12
  • Resistance Level
  • BCAB $1.06
  • GNSS $2.24
  • Average True Range (ATR)
  • BCAB 0.14
  • GNSS 0.12
  • MACD
  • BCAB -0.03
  • GNSS -0.02
  • Stochastic Oscillator
  • BCAB 22.48
  • GNSS 22.86

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

Share on Social Networks: